

Certificate of Analysis

Kit (V560G), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-730, 14-730-K, 14-730M

Parent Lot # 33074U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST tagged, recombinant human Kit, amino acids 544–end containing the V560G mutation. Expressed in Sf21 insect cells. Purified using glutathione agarose. The V560G mutation has been found in patients with gastrointestinal stromal tumours and has been linked to poor prognosis. This mutation confers increased susceptibility to Gleevec®. (Frost MJ *et al.*, American Cancer Therapeutics, (2002);1:1115-1124 & Cullinane C *et al.*, Cancer Research, (2005);65:9633-9636) Purity 80.5% by SDS-PAGE and Coomassie blue staining. MW = 76.6kDa.

Specific Activity (Parent lot# 33074U): 116U/mg, where one unit of Kit (V560G) activity is defined as 1nmol phosphate incorporated into 250µM (GGMEDIYFEFMGGKKK) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.831mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 83.1–415.5ng of this lot of enzyme phosphorylated 250µM (GGMEDIYFEFMGGKKK) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as Kit (V560G) with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. (GGMEDIYFEFMGGKKK):** Use at a final assay concentration of 250 μ M. Make up a 2.5mM stock. Add 2.5 μ l of stock per assay point.
- 3. Kit (V560G), active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 83.1–415.5ng per assay point.
- 4. [γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per well.
2. Add 2.5 μ l of (GGMEDIYFEFMGGKKK).
3. Add 2.5 μ l (83.1–415.5ng) Kit (V560G), active.
4. Add 5 μ l dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

Kit (V560G) Sequence Information

<u>Protein</u>	human Kit (V560G)
<u>Tags</u>	N-terminal GST
<u>Native sequence</u>	T237 of the recombinant sequence is equivalent to T544 of the native human Kit
<u>Accession number</u>	GenBank X06182

Recombinant-Kit (V560G) amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMA  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121  DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181  KRIEAIPQID  KYLKSSKYIA  WPLQGWQATF  GGDHPPKSD  LEVLFQGPPEF  KGLRRQTYKY
241  LQKPMYEVQW  KVGEEINGNN  YVYIDPTQLP  YDHKWEFPRN  RLSFGKTLGA  GAFGKVVEAT
301  AYGLIKSDAA  MTVAVKMLKP  SAHLTEREAL  MSELKVLSTL  GNHMNIVNLL  GACTIGGPTL
361  VITEYCCYGD  LLNFLRRKRD  SFICSKQEDH  AEALYKNLL  HSKESSCSDS  TNEYMDMKPG
421  VSYVPTKAD  KRRSVRIGSY  IERDVTPAIM  EDDELALDLE  DLLSFSYQVA  KGMAFLASKN
481  CIHRDLAARN  ILLTHGRITK  ICDFGLARDI  KNDSNYVVKG  NARLPVKWMA  PESIFNCVYT
541  FESDVWSYGI  FLWELFSLGS  SPYPGMPVDS  KFYKMIKEGF  RMLSPEHAPA  EMYDIMKTCW
601  DADPLKRPTF  KQIVQLIEKQ  ISESTNHIYS  NLANCSPNRQ  KPVDHVSURI  NSVGSTASSS
661  QPLLVDHVV

```

Recombinant Kit (V560G) nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aagggccttg  tgcaaccac  togacttctt
61  ttggaatata  ttgaagaaa  atatgaagag  catttgatg  agcgcgatga  aggtgataaa
121  tggcgaaaca  aaaagttag  attgggtttg  gaggttccca  atcttcctta  ttatattgat
181  ggtgatgata  aattaacaca  gtctatggcc  atcatacgtt  atatagctga  caagcacaac
241  atgttgggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcgggtttg
301  gatattagat  acgggtgttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gatcttctta  gcaagctacc  tgaatgctcg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acatatatta  atggatgata  tgtaaccat  cctgacttca  tgttgatgata  cgctcttgat
481  gttgttttat  acatggacc  aatgtgctcg  gatgcttcc  caaaattagt  ttgttttaaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggaagttc  tgttccagg  gcccgaaatc  aaaggcctac  gtcgacaaac  ctacaaatat
721  ttacagaaac  ccatgatatga  agtacagtgg  aagggtgggtg  aggagataaa  tggaaacaat
781  tatgtttaca  tagaccaca  acaacttctc  tatgatcaca  aatgggagtt  tcccagaaac
841  aggctgagtt  ttgggaaaac  cctgggtgct  ggagcttctc  ggaaggttgt  tgaggcaact
901  gcttatggct  taattaagtc  agatgctgac  atgactgtcg  ctgtaaagat  gctcaagccg
961  agtgcccatt  tgacagaacg  ggaagccctc  atgtctgaac  tcaaagtcct  gagttacctt
1021  ggtaatacaca  tgaatattgt  gaacttactt  ggagcctgca  ccattggagg  gccaccctg
1081  gtcattacag  aatattgttg  ctatggtgat  cttttgaatt  ttttgagaag  aaaacgtgat
1141  tcatttattt  gttcaaagca  ggaagatcat  gcagaagctg  cactttataa  gaacttctc
1201  cattcaaagg  agtcttcctg  cagcgatagt  actaatgagt  acatggacat  gaaacctgga
1261  gtttcttatg  ttgtcccaac  caaggccgac  aaaaggagat  ctgtgagaat  aggtcctaac
1321  atagaaagag  atgtgactcc  cgccatcatg  gaggatgacg  agttggccct  agacttagaa
1381  gacttgctga  gcttttctta  ccaggtggca  aagggcattg  ctttctctcg  ctccaagaat
1441  tgtattcaca  gagacttggc  agccagaaat  atcctcctta  ctcatggtcg  gatcacaaag
1501  atttgtgatt  ttggtctagc  cagagacatc  aagaatgatt  ctaattatgt  ggttaaagga
1561  aacgctcgac  tacctgtgaa  gtggatggca  cctgaaagca  ttttcaactg  tgtatacacg
1621  tttgaaagtg  acgtctggtc  ctatgggatt  tttctttggg  agctgttctc  tttaggaagc
1681  agcccctatc  ctggaatgcc  ggtcgattct  aagttctaca  agatgatcaa  ggaaggcttc
1741  cgatgctca  gccctgaaca  cgcacctgct  gaaatgtatg  acataatgaa  gacttgctgg

```

Certificate of Analysis

```
1801 gatgcagatc ccctaaaaag accaacattc aagcaaattg ttcagctaat tgagaagcag
1861 atttcagaga gcaccaatca tatttactcc aacttagcaa actgcagccc caaccgacag
1921 aagcccgtgg tagaccattc tgtgCGGatc aattctgtcg gcagcaccgc ttcctcctcc
1981 cagcctctgc ttgtgcacga cgatgtctga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.